Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics.

The Lancet. Neurology·2026
Same author

Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.

Lancet (London, England)·2026
Same author

Socioeconomic impact of depression and pain in patients with neuromyelitis optica spectrum disorders.

Neurological research and practice·2026
Same author

Glatiramer acetate stimulates phagocytosis and intracellular killing of <i>Escherichia coli</i> by macrophages and microglial cells.

Frontiers in immunology·2026
Same author

Microglia-associated progression of multiple sclerosis: target identification and therapeutic engagement in human in vitro models.

Experimental & molecular medicine·2026
Same author

Cellular and humoral vaccination response under immunotherapies-German consensus on vaccination strategies in neurological autoimmune diseases.

Therapeutic advances in neurological disorders·2025

Related Experiment Video

Updated: Nov 10, 2025

Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility
07:54

Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility

Published on: April 13, 2017

10.1K

Microglia: The Missing Link to Decipher and Therapeutically Control MS Progression?

Anastasia Geladaris1, Darius Häusler1, Martin S Weber1,2

  • 1Department of Neuropathology, University Medical Center, 37075 Göttingen, Germany.

International Journal of Molecular Sciences
|April 3, 2021
PubMed
Summary
This summary is machine-generated.

Understanding microglia

Keywords:
disease progressionmicrogliamultiple sclerosistargetstherapy

More Related Videos

Assessing Microglial Phagocytosis of Myelin Debris in vitro Under Repeated Magnetic Stimulation
08:34

Assessing Microglial Phagocytosis of Myelin Debris in vitro Under Repeated Magnetic Stimulation

Published on: June 17, 2025

680
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.5K

Related Experiment Videos

Last Updated: Nov 10, 2025

Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility
07:54

Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility

Published on: April 13, 2017

10.1K
Assessing Microglial Phagocytosis of Myelin Debris in vitro Under Repeated Magnetic Stimulation
08:34

Assessing Microglial Phagocytosis of Myelin Debris in vitro Under Repeated Magnetic Stimulation

Published on: June 17, 2025

680
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.5K

Area of Science:

  • Neuroimmunology
  • Neurobiology
  • Multiple Sclerosis Pathogenesis

Background:

  • Chronic progression in multiple sclerosis (MS) is a significant therapeutic challenge.
  • MS progression involves steady central nervous system (CNS) damage, independent of relapses.
  • Mechanisms of MS progression differ from relapse-related inflammation.

Purpose of the Study:

  • To review the role of microglia in multiple sclerosis progression.
  • To explore potential therapeutic targets related to microglial activation in MS.

Main Methods:

  • Literature review of current research on microglia and MS progression.
  • Analysis of the dual role of microglia in neurodegeneration and neuroprotection.
  • Discussion of therapeutic strategies targeting microglial function.

Main Results:

  • Microglia, CNS-resident immune cells, are implicated in MS progression.
  • Microglial function is plastic, capable of promoting neurotoxicity or neuroprotection.
  • Dysregulated microglial activation may drive neurodegeneration in progressive MS.

Conclusions:

  • Targeting microglial activation presents a promising therapeutic avenue for progressive MS.
  • Modulating microglial phenotypes could halt or reverse CNS damage in MS.
  • Further research into microglial pathways is crucial for developing effective MS treatments.